Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-126-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0018H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Cultural lysates (HEK), Whole blood

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 9.6%

Inter-assay (Run-to-Run)

n = 5,
CV = 7.8%

Spiking Recovery

106.0%

Dilutation Linearity

102.2%

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-126-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases. The gene for miR-126 is located on chromosome 9. miR-126-3p is endothelial-specific miRNA that regulates angiogenesis and blood vessel integrity. miR-126-3p also regulates expression of many cancer-related genes. Studies suggest that miR-126-3p acts as either a tumor suppressor or an oncogene in different types of cancer. Lower expression of miR-126-3p has been reported to be associated with poor prognosis in hepatocellular carcinoma. Furthermore, overexpression of miR-126-3p significantly reduced tumor size. The expression of miR-126-3p was also downregulated in malignant thyroid tumor samples when compared to benign thyroid tumor samples. On the other hand, decreased miR-126-3p expression is associated with clinically more aggressive papillary thyroid cancer. It was shown that levels of miR-126-3p in endothelial cell microparticles are abnormal in subjects with pre-diabetes and correlate with well-accepted markers of endothelial dysfunction. It was demonstrated that downregulated plasma level of miR-126-3p in patients with type 2 diabetes is associated with diabetic vascular complications. It was also found that miR-126-3p regulates lipid metabolism through targeting the genes related to lipid synthesis. Several groups have revealed that miR-126-3p levels are low in serum of stable coronary artery disease patients, and that there is a positive association between circulating miR-126-3p and myocardial infarction. Significantly lower level of miR-126-3p expression was observed in severe coronary artery disease patients compared to the healthy subjects.

References to Summary

References to miR-126-3p

  • Fish, Jason E., et al. "miR-126 regulates angiogenic signaling and vascular integrity." Developmental cell 15.2 (2008): 272-284.
  • Xiong, Yin, et al. "miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer." PloS one 10.8 (2015): e0130496.
  • Li, Zejuan, and Jianjun Chen. "In vitro functional study of miR-126 in leukemia." MicroRNA and Cancer: Methods and Protocols(2011): 185-195.
  • Liu, Yaling, et al. "MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways." International journal of oncology 44.1 (2014): 203-210.
  • Du, Chengli, et al. "MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2." Journal of translational medicine 12.1 (2014): 259.
  • Kitano, Mio, et al. "Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs." Annals of surgical oncology 18.12 (2011): 3443.
  • Giannella, Alessandra, et al. "Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance." Cardiovascular diabetology 16.1 (2017): 118.
  • Olivieri, Fabiola, et al. "MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications." Oncotarget 6.34 (2015): 35372.
  • Chu, Meiqiang, et al. "MicroRNA-126 participates in lipid metabolism in mammary epithelial cells." Molecular and Cellular Endocrinology (2017).
  • Zampetaki, Anna, et al. "Prospective study on circulating MicroRNAs and risk of myocardial infarction." Journal of the American College of Cardiology 60.4 (2012): 290-299.
  • Fichtlscherer, Stephan, et al. "Circulating microRNAs in patients with coronary artery diseasenovelty and significance." Circulation research 107.5 (2010): 677-684.
  • Qu, Qingxi, et al. "Upregulation of miR-126-3p promotes human saphenous vein endothelial cell proliferation in vitro and prevents vein graft neointimal formation ex vivo and in vivo." Oncotarget8.63 (2017): 106790.
Related Products Documents